Scopolamine

Quick links to important sections

Scopolamine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scopolamine

What is Scopolamine? A Foundational Overview

Property Description
Active ingredient Hyoscine Butylbromide (INN)
Pharmacological class Anticholinergic agent / Spasmolytic
Origin Semi-synthetic derivative of a natural tropane alkaloid
Common purpose Relief of painful smooth muscle spasms (cramping)
Forms Tablet, solution for injection, suppository

What is Hyoscine Butylbromide and What Type of Drug Is It?

Hyoscine Butylbromide is the generic name (INN) for a medication classified primarily as an anticholinergic agent (antimuscarinic) and used specifically as a spasmolytic to relax internal muscles. This compound is a semi-synthetic derivative of the naturally occurring tropane alkaloid Scopolamine (L-hyoscine). Chemically, it is a quaternary ammonium derivative of the parent molecule, a structural feature that significantly restricts its ability to easily pass the blood-brain barrier. This differentiating factor ensures the drug’s effects are primarily localized to the body's periphery, targeting the muscles of the digestive and urinary tracts, while minimizing central nervous system effects associated with non-quaternary anticholinergics. Its efficacy in managing visceral pain is recognized.


What is the General Purpose of This Spasmolytic Agent?

The overarching purpose of this medicine is to provide relief from the sharp, painful involuntary tightening, or spasms, affecting the smooth muscles found in organs like the intestines and bladder. It functions as a powerful smooth muscle relaxant by acting as a non-selective muscarinic antagonist, blocking nerve signals from the parasympathetic nervous system that trigger these muscles to contract excessively. This action interrupts the signal flow mediated by acetylcholine, thereby stopping hypermotility and allowing the affected muscles to return to a relaxed state, managing the acute cramping pain that often accompanies conditions involving visceral spasms.


What Forms of Hyoscine Butylbromide Are Available?

Hyoscine Butylbromide is manufactured as a single-active ingredient product and is made available in different forms for versatile administration, including tablets for oral ingestion and a solution for injection for parenteral (e.g., intravenous or intramuscular) delivery. The composition consists of the active ingredient within either solid excipients for the tablets or an aqueous base for the injection. The availability of both oral and parenteral forms is a key differentiating feature for healthcare professionals, ensuring flexibility in treatment—allowing for convenient relief from spasms with tablets and rapid, crucial action with injection for acute episodes.

What side effects are possible with Scopolamine?

Possible Side Effects and Safety Information

The safety profile of Hyoscine Butylbromide (Scopolamine Butylbromide) is based exclusively on information documented in regulatory sources, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). The adverse reactions are primarily anticholinergic in nature and are officially classified by frequency and System-Organ Class (SOC).


Official Adverse Reactions and Frequency

The following is a selection of reactions categorized by their frequency as documented in regulatory labels:

Classification Examples of Reactions
Uncommon Hypersensitivity reactions (e.g., skin rash), Tachycardia (increased heart rate), Dyshidrosis (reduced sweating).
Rare Accommodation disturbances (temporary blurred vision), Dry mouth.
Very Rare Severe Central Nervous System effects (e.g., confusion, hallucinations, coma) following parenteral administration.

Serious Adverse Reactions and Restrictions

Official documents list several reactions considered serious or clinically significant. These include anaphylactic shock and marked hypotension (especially with intravenous injection), severe urinary retention, and the potential precipitation of acute narrow-angle glaucoma.

Use of Hyoscine Butylbromide is strictly contraindicated in individuals with pre-existing conditions such as untreated narrow-angle glaucoma, prostatic hypertrophy with urinary retention, megacolon, and mechanical stenosis of the gastrointestinal tract.

Population-Specific Safety Notes

  • Geriatrics (Older Adults): Increased sensitivity to anticholinergic effects is noted, including a potential for dizziness and confusion.
  • Pediatrics: The medication is generally not recommended for children under 6 years of age in many regulatory documents.
  • Pregnancy and Lactation: Official labels indicate that use is generally not recommended due to insufficient data regarding safety.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The officially documented clinical manifestations of Hyoscine Butylbromide overdosage are consistent with its peripheral anticholinergic activity. These signs include urinary retention, dry mouth, reddening of the skin, tachycardia (increased heart rate), inhibition of gastrointestinal motility, and transient visual disturbances. While regulatory documents note that serious signs of poisoning have not been observed in man following acute overdosage, severe complications such as respiratory paralysis have been documented, necessitating immediate procedural intervention.


Required Emergency Actions

Immediate medical advice should be sought if severe, unexplained abdominal pain persists or worsens, or occurs together with associated symptoms like fever, nausea, vomiting, fainting, or blood in stool. This direction provides the regulator-mandated trigger for urgent help.

Overdose symptoms typically respond to parasympathomimetics. Officially described management procedures involve specific supportive measures, such as gastric lavage followed by activated charcoal for oral poisoning, and catheterisation for persistent urinary retention. For patients with narrow-angle glaucoma, local administration of pilocarpine is documented as a necessary step to manage potential ocular complications.

Therapeutic Uses of Scopolamine

Scopolamine is commonly used across domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort and systemic imbalance. These therapeutic applications are recognized for contributing to easing the overall symptom load.

The medication is applied in addressing symptoms that interfere with daily functioning across conditions like motion sickness, postoperative nausea and vomiting (PONV), and the management of excessive bodily secretions, such as sialorrhea (drooling). In settings where short-term symptom management is appropriate, scopolamine provides support that helps ease the overall burden of symptoms.

“The medication may assist with maintaining a sense of stability during difficult episodes.”


Quick Fact: Relevant for Managing Nausea and Vomiting Symptoms

Scopolamine is particularly relevant in clinical settings that involve acute or unstable symptom patterns, such as the period following surgery, where it offers symptomatic relief that helps patients cope more steadily.

Eligibility and Restrictions for Use

Who Can and Cannot Use Scopolamine? Official Regulatory Information

Official regulatory documentation classifies eligibility based on absolute contraindications and population restrictions.

Category Official Regulatory Classification
Contraindicated Populations Patients with angle-closure glaucoma, myasthenia gravis, or mechanical stenosis in the gastrointestinal or urinary tracts.
Age-Related Restrictions Children under 10 years (transdermal system) or under 6 years (oral tablets) are generally not recommended or use is not established.
Life-Stage Restrictions Use during pregnancy or lactation is not recommended due to insufficient data, with specific warnings against use in severe preeclampsia.
Conditional Use Populations Older adults and individuals with impaired renal or hepatic function require caution and monitoring due to increased risk of central nervous system effects.

Eligibility is strictly prohibited for individuals with conditions susceptible to anticholinergic effects, such as pre-existing glaucoma or intestinal obstruction (paralytic ileus). Use is also limited by age, as safety and efficacy have not been formally established across all pediatric groups.

What should I know about interactions with other medicines?

Scopolamine Interactions with Other Medicines and Products

This section outlines interactions with other medicinal products and substances as documented in official government regulatory information.


Documented Pharmacodynamic Interactions

Co-administration with certain agents may result in additive effects:

  • CNS Depressants: Combining Scopolamine with substances like sedatives, opioids, or alcohol (ethanol) is documented to increase the risk of amplified central nervous system effects, such as drowsiness and dizziness.
  • Anticholinergic Drugs: Use with other anticholinergic agents, including tricyclic antidepressants or certain antihistamines, carries an increased risk of intensified peripheral anticholinergic side effects (e.g., dry mouth, blurred vision, urinary retention).
  • Dopaminergic Antagonists: Drugs like metoclopramide or domperidone may reduce the spasmolytic effect of Hyoscine Butylbromide due to antagonistic action on gastrointestinal motility.

Absorption and Timing Constraints

Scopolamine's effect on gastrointestinal motility can delay the absorption of co-administered oral medications.

  • Antacids / Adsorbent Drugs: Products such as antacids or adsorbent anti-diarrhea drugs can reduce the absorption of oral Scopolamine and should be administered at least one hour apart.
  • Diagnostic Interference: Scopolamine must be discontinued before a gastric secretion test as it interferes with the procedural results.

Formal Interaction Restrictions

  • Contraindicated Combination: Co-administration with potassium chloride wax matrix tablets is formally prohibited due to the documented risk of gastrointestinal lesions.
  • Population Notes: Caution is advised in elderly patients and those with impaired renal or hepatic function due to increased susceptibility to CNS adverse reactions from interacting substances.

Mechanism of Action

️ How Scopolamine Works: Mechanism of Action


Molecular Blockade of Cholinergic Signals

The core mechanism involves Hyoscine Butylbromide acting as a competitive antagonist at the Muscarinic Acetylcholine Receptors (M1–M5 subtypes). By binding reversibly to these sites, the molecule physically prevents the natural neurotransmitter, Acetylcholine ( ACh), from triggering the signal cascade that normally initiates muscle contraction.


Targeting the Peripheral Parasympathetic Pathway

This receptor blockade primarily targets the postganglionic nerve endings of the Peripheral Parasympathetic Nervous System. Crucially, the drug's quaternary ammonium structure prevents it from significantly crossing the blood-brain barrier , ensuring its anticholinergic effect is localized to the visceral smooth muscles of the gastrointestinal and genitourinary tracts.


Physiological Consequence: Smooth Muscle Relaxation

The interruption of the cholinergic signal cascade halts the process of muscle depolarization. This suppression of excessive, involuntary contractions (hypermotility and hypertonia) results in the relaxation of the smooth muscle tissue. This change represents the physiological shift from a state of hypertonia initiated by neural overstimulation to a state of muscle relaxation.

Dosage and Administration Information

The administration of Scopolamine involves distinct protocols based on the chemical form and intended route, utilizing Hyoscine Butylbromide for spasmolytic action and Scopolamine for anti-emetic use.


Administration Routes and Dosing

Hyoscine Butylbromide is used for oral ingestion as a tablet and for parenteral injection (intravenous, intramuscular, or subcutaneous). The standard adult oral regimen involves taking 10 mg to 20 mg per dose, which may be repeated up to three to five times daily, if required. Oral tablets are generally taken with or without food. For acute episodes, the injection solution is often dosed at 20 mg, repeatable after 30 minutes, adhering to a strict maximum daily dose of 100 mg.

The Scopolamine transdermal system is used topically for anti-emetic purposes. This formulation is designed to deliver approximately 1 mg of the compound over a 72-hour period. Instructions require applying one patch to the clean, hairless skin of the postauricular area (behind the ear) at least four hours before the anti-emetic effect is desired.


Procedural Requirements and Time Constraints

Usage is further defined by time constraints and specific procedural requirements. Only one patch should be worn at any time, and if therapy must continue beyond 72 hours, the first patch must be removed, and a new one applied to the opposite postauricular area. The transdermal system must be removed before certain medical imaging procedures, such as a Magnetic Resonance Imaging (MRI) scan. For pediatric use, the transdermal patch is not recommended, while 10 mg oral tablets are typically administered to children over six years of age, subject to regional guidance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Scopolamine

The clinical evaluation of Scopolamine and its derivative, Hyoscine Butylbromide, focuses on several distinct clinical situations, with evidence primarily derived from Randomized Controlled Trials (RCTs) and Systematic Reviews.


Evidence for Use in Preventing Postoperative Nausea and Vomiting (PONV)

Research has explored the transdermal formulation's role in outcomes related to postoperative nausea and vomiting in adult patients following surgery. Studies monitored the incidence of nausea and vomiting and the utilization of rescue antiemetic medications. Systematic reviews reported measurements of differences in the incidence of these symptoms compared to placebo. However, follow-up durations were limited, typically focusing only on the first 24 to 48 hours post-procedure.

Evidence for Preventing Motion Sickness

The medicine was studied for outcomes related to motion sickness symptoms in healthy adults exposed to controlled motion. Studies monitored symptom patterns and reported measurements of differences in the frequency of nausea and vomiting when the study medicine was used compared to placebo. A key limitation is that research primarily explored outcomes related to prophylaxis (prevention), and the evidence base for addressing established symptoms is limited.

Evidence for Relief of Acute Smooth Muscle Spasms

The derivative formulation was evaluated in trials examining outcomes related to acute, painful episodes, predominantly involving adults presenting with abdominal cramping. Trials monitored changes in pain scores over short time intervals (e.g., 30 to 60 minutes). Findings were mixed when the drug was used to address acute, undifferentiated abdominal pain, with some trials reporting no measurable difference from placebo. Long-term outcomes are not well characterized, as data are limited to the immediate relief period.

What is Still Uncertain About the Available Research

The overall evidence highlights several limitations. Follow-up durations were limited across most indications. Comparative evidence is lacking in some areas, and sample sizes were small in many individual trials. Furthermore, the certainty of evidence varies across studies, and data for certain groups remain insufficient, particularly dedicated data for younger children.

Key Studies & References

  1. Transdermal scopolamine for reduction of drooling in developmentally delayed children.
  2. SCOPOLAMINE patch - DailyMed (FDA-mandated labeling for Scopolamine Transdermal System).

Frequently Asked Questions (FAQ)

Common questions about Scopolamine (FAQ)


Q: Is it normal to feel dizzy when using Scopolamine?

Official product information states that dizziness is listed as a potential common side effect when using the medicine. Official warnings recommend caution during use if a person experiences drowsiness or dizziness.


Q: Can Scopolamine make you sleepy or drowsy?

According to regulatory documents, drowsiness or unusual sleepiness is a common side effect of this medicine. Due to this potential effect, official warnings caution against certain activities while using Scopolamine.


Q: How quickly does Scopolamine start working?

Official instructions for the transdermal patch state it should be applied at least four hours before the anti-emetic effect is desired. After application, peak levels of the medicine in the bloodstream are typically reached sometime between eight and 24 hours.


Q: Are there any common side effects besides drowsiness?

The most commonly reported side effect in official prescribing information is dry mouth. Other common effects documented in regulatory sources include blurred vision, confusion, and dizziness.


Q: Is Scopolamine used for motion sickness on cruise ships?

Official prescribing information confirms that Scopolamine is FDA-approved for the prevention of nausea and vomiting that is associated with motion sickness.


Q: Does Scopolamine help with vomiting or nausea that isn't from motion sickness?

In addition to motion sickness, Scopolamine is also FDA-approved for the prevention of postoperative nausea and vomiting (PONV). This use is typically associated with recovery after surgery and anesthesia.


Q: Is there a limit to how many days in a row I can use the Scopolamine patch?

Each transdermal patch is designed to deliver medicine for up to three days. Official guidance describes removing the old patch and applying a new one to the opposite area for continued therapy. Using the patch continuously for longer periods may increase the potential for withdrawal symptoms upon discontinuation, according to official information.


Q: How does Scopolamine affect the central nervous system?

Scopolamine acts in the central nervous system (CNS) by blocking signals in certain pathways. According to official documents, potential CNS effects can include drowsiness, dizziness, and confusion.


Q: What are the symptoms of 'anticholinergic syndrome' related to Scopolamine?

The medicine is an anticholinergic agent, and official documents list effects such as dry mouth, blurred vision, and difficulty urinating. Rare and more serious psychiatric effects have also been reported, including acute toxic psychosis, which involves severe confusion, agitation, and hallucinations.


Q: Can you wear the scopolamine patch while swimming or showering?

Official instructions advise that patients limit contact with water while swimming or showering. This caution is advised because excessive water exposure may cause the patch to fall off.


Q: What happens if I forget to remove the patch after the recommended time?

Official documentation states that if the patch is used for a prolonged period, there is an increased potential for withdrawal symptoms upon removal. These symptoms reported in studies include dizziness, nausea, and headaches.


Q: Why is Scopolamine sometimes given before surgery?

The transdermal patch has an FDA-approved indication for the prevention of postoperative nausea and vomiting (PONV). For this preventative, or prophylactic, effect, the patch is often applied the evening before a scheduled surgery.


Q: Can I use Scopolamine if I have glaucoma?

Official FDA information lists angle-closure glaucoma as a contraindication for the medicine. For patients with chronic open-angle glaucoma, official sources advise that the condition should be monitored during use.


Q: Is Scopolamine addictive?

Official information advises that scopolamine may potentially induce dependence. Regulatory sources also indicate that withdrawal symptoms may follow discontinuation, especially after prolonged use.


Q: Can people who are pregnant use Scopolamine?

Regulatory agencies advise that the use of Scopolamine during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus, as the drug crosses the placenta. The medicine is also excreted into human milk and may potentially inhibit lactation.


Q: Why do some people experience hallucinations or confusion when using Scopolamine?

Official documents list confusion, hallucinations, and other psychiatric reactions as rare, serious adverse effects. This risk is noted to be higher in certain susceptible populations, such as older adults.


Q: What are the official warnings about Scopolamine and operating heavy machinery?

Official regulatory information includes a warning that Scopolamine can cause drowsiness, disorientation, and confusion. Official warnings describe avoiding activities that require mental alertness, such as driving or operating machinery, when using this medicine.


Q: What is the proper way to dispose of the Scopolamine patch?

Patients are advised in official documentation that used patches should be disposed of properly to prevent contact with children or pets. The general guidance from regulatory sources is to dispose of contents or container at an approved waste disposal plant.


Q: Can Scopolamine affect my heart rate?

Official reports indicate that Scopolamine may potentially affect heart rate. The possibility of an increase in heart rate, known as tachycardia, is listed as a potential side effect in regulatory documents.


Q: What are the documented signs of Scopolamine overdose?

Documented signs of Scopolamine overdose listed in regulatory sources include changes in vision, increased anxiety, confusion, and difficulty with urination. Other reported physical signs include dry and flushed skin, and a fast or irregular heartbeat.


Q: Why is Scopolamine sometimes referred to as 'hyoscine'?

Scopolamine is chemically known as hyoscine, and the two terms are often used interchangeably in scientific literature. Furthermore, the form of the drug used for spasmolytic action is Hyoscine Butylbromide, which is a chemical derivative.


Q: What should I do if the patch falls off?

According to official instructions, if the patch falls off, official instructions state that the patch should be discarded, and a replacement patch can then be applied. The new patch should be placed on the hairless area behind the other ear.


Q: Can Scopolamine cause memory issues?

Official regulatory documents note that memory issues are potential side effects of Scopolamine use. This includes reports of memory loss and memory impairment related to new information.


Q: How long does Scopolamine stay in your system after removing the patch?

Pharmacokinetic data indicates that after the transdermal patch is removed, scopolamine can remain in the skin layers and continue to be absorbed by the body. The reported half-life of the medicine in the body is approximately nine hours.


Q: Is it possible to be allergic to Scopolamine?

Official prescribing information lists hypersensitivity, which is the medical term for a severe allergic reaction, to Scopolamine or other related belladonna alkaloids as a contraindication.

How should Scopolamine be stored and disposed of?

How to Store and Dispose of Scopolamine

Official regulatory labeling dictates strict conditions for the storage and disposal of scopolamine products to maintain stability and prevent accidental exposure.


Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Protect from moisture and freezing.
Container Store in the original sealed foil pouch or tightly closed container.
Child Safety Keep out of the sight and reach of children.

Disposal Protocol

Used scopolamine patches must be folded in half with the sticky sides together before being discarded in the household trash immediately upon removal. Unused or expired medication should not be flushed down the toilet and must be disposed of via a drug take-back program or according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Scopolamine found in:

A-Z Index: